Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 197-202

  Smorenburg, Carolien H ^a   Sparreboom, Alex ^a   Bontenbal, Marijke ^a   Stoter, Gerrit ^a   Nooter, Kees ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; PACLITAXEL; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD VOLUME; BODY SIZE; BODY SURFACE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISPOSITION; HUMAN; LEAN BODY WEIGHT; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; ADULT; AGED; ANIMAL; DOSE RESPONSE; FEMALE; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BODY SURFACE AREA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 0037440224     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.058     Document Type: Article

References (32)

1. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
2. Sawyer M, Ratain MJ: Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177, 2001
3. Grochow LB, Baraldi C, Noe D: Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82:323-325, 1990
4. Reilly JJ, Workman P: Normalisation of anti-cancer drug dosage using body weight and surface area: Is it worthwhile? Cancer Chemother Pharmacol 32:411-418, 1993
5. Choy H: Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 37:237-247, 2001
6. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
7. Mathijssen RHJ, Verweij J, de Jonge MJ, et al: Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20:81-87, 2002
8. Sparreboom A, de Bruijn P, Nooter K, et al: Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 705:159-164, 1998
9. Brouwer E, Verweij J, de Bruijn P, et al: Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 28:1141-1145, 2000
10. Sparreboom A, Loos WJ, Verweij J, et al: Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255:171-175, 1998
11. Henningsson A, Karlsson MO, Vigano L, et al: Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19:4065-4073, 2001
12. Gelderblom H, Mross K, Verweij J, et al: Comparative pharmacokinetics of unbound paclitaxel during 1-and 3-hour infusions. J Clin Oncol 20:574-581, 2002
13. Sparreboom A, Spicer D, Verweij J, et al: Effect of valspodar (PSC 833) on the pharmacokinetics of unbound paclitaxel. Proc Am Assoc Cancer Res 42:535-536, 2001 (abstr)
14. van Zuylen L, Karlsson MO, Verweij J, et al: Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47:309-318, 2001
15. Julious SA, Campbell MJ, Altman DG: Estimating sample sizes for continuous, binary, and ordinal outcomes in paired comparisons: Practical hints. J Biopharm Stat 9:241-251, 1999
16. De Jongh FE, Verweij J, Loos WJ, et al: Body-surface area-based dosing does not increase accuracy of predicting cisplaiin exposure. J Clin Oncol. 19:3733-3739, 2001
17. Gurney HP, Ackland S, Gebski V, et al: Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299-2304, 1998
18. Loos WJ, Gelderblom H, Sparreboom A, et al: Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens. Clin Cancer Res 6:2685-2689, 2000
19. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al: Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations, with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309-319, 2002
20. Goh BC, Ratain MJ, Bertucci D, et al: Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 19:1476-1484, 2001
21. Felici A, Verweij J, Sparreboom A: Dosing strategies for anticancer agents: The good, the bad and body-surface area. Eur J Cancer 38:1674-1681, 2002
22. Van Zuylen L, Verweij J, Sparreboom A: Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125-141, 2001
23. Sparreboom A, van Zuylen L, Brouwer E, et al: Cremophor EL- mediated alteration of paclitaxel distribution in blood: Clinical pharmacokinetic implications. Cancer Res 59:1454-1457, 1999
24. Sparreboom A, Verweij J, van der Burg MEL, et al: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937-1942, 1998
25. Van den Bongard HJGD, Mathot RAA, Van Tellingen O, et al: A population analysis of the pharmacokinetics of Cremophor EL using non-linear mixed-effect modeling. Cancer Chemother Pharmacol 50:16-24, 2002
26. Baker RJ, Kozoll DD, Meyer KA: The use of surface area as a basis for establishing normal blood volume. Surg Gynecol Obst 104:183-189, 1957
27. Rahman A, Korzekwa KR, Grohan J, et al: Selective biotransformation of taxol to 6 alpha-hydrotaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546, 1994
28. Sparreboom A, van Asperen J, Mayor U, et al: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031-2035, 1997
29. Tayeb MT, Clark C, Ameyaw MM, et al: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10:753-756, 2000
30. Dai D, Zeldin DC, Blaisdell JA, et al: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607, 2001
31. Ameyaw MM, Regateiro F, Li T, et al: MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11:217-221, 2001
32. Smorenburg CH, Ten Tije AJ, Verweij J, et al: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer (in press)